Accelerate Drug Development for Duchenne

Fostering a multi-stakeholder collaboration to accelerate our causes.

Despite major advancements in treatment options over the past few decades, Duchenne muscular dystrophy remains a fatal disease with limited options. There is a pressing need to accelerate the evaluation and introduction of effective, targeted therapies for children and adolescents with Duchenne.

WDO aspires to engage with the international community to accelerate its mission and vision for care and a cure for people living with Duchenne.

Accelerate Platform for Duchenne aims to bring together key stakeholders, including academia, industry, advocacy, and regulatory bodies, to collaborate on finding solutions for better and more innovative therapies for children and adolescents with Duchenne.